Evidence map›Paper›PMID 40759914›Full record

Observational studyBMC geriatrics2025

Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS).

Roger A Fielding, Yves Rolland, Olivier Bruyere, Moise Desvarieux, Lorenzo M Donini, Raffaele Antonelli Incalzi, Maurizio Muscaritoli, Achille Tchalla, Marc Bonnefoy, Mariangela Rondanelli and 7 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03021798 (Characterising SARcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over at Risk of Mobility Disability. An OBServational Clinical Trial), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03021798 completednot on this map

Characterising SARcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over at Risk of Mobility Disability. An OBServational Clinical Trial (SARA-OBS)

TypeobservationalSponsorBiophytisRan2017 to 2020Enrolled218ConditionsSarcopenia, Gait Disorders in Old Age, Muscle WeaknessArmsNo Drug and no aspecific intervention
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Roger A FieldingNutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, 711 Washington St, Boston, MA, 02111, USA.
Yves RollandIHU HealthAge, Centre Hospitalo-Universitaire de Toulouse, CERPOP UMR 1295, University of Toulouse III, Toulouse, France.
Olivier BruyereWHO Collaborating Center for Public Health aspects of musculo-skeletal health and ageing, Research Unit in Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
Moise DesvarieuxDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Lorenzo M DoniniDepartment of Experimental Medicine, Food Science and Human Nutrition Research Unit, Sapienza University of Rome, Rome, Italy.
Raffaele Antonelli IncalziInternal Medicine Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Maurizio MuscaritoliDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Achille TchallaCHU de Limoges, Pôle HU Gérontologie Clinique, 2 Avenue Martin-Luther King, Limoges, 87042, France.
Marc BonnefoyCHLS, Pavillon 4E, Service Universitaire de Médecine gériatrique, INSERM 1060, UCBL LYON 1, Pierre Benite CEDEX, 69495, France.
Mariangela RondanelliDepartment of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, 27100, Italy.
Rob Van MaanenBIOPHYTIS SA - Sorbonne Université, 4 Place de Jussieu, Paris Cedex 05, 75252, Italy.
Jean MarianiBIOPHYTIS SA - Sorbonne Université, 4 Place de Jussieu, Paris Cedex 05, 75252, Italy.
Carole MargalefBIOPHYTIS SA - Sorbonne Université, 4 Place de Jussieu, Paris Cedex 05, 75252, Italy.
Susanna Del SignoreBluecompanion Ltd, 12a Neville Court, Abbey Road, London, NW8 9DD, UK.
Cendrine TouretteBIOPHYTIS SA - Sorbonne Université, 4 Place de Jussieu, Paris Cedex 05, 75252, Italy.
Waly DiohBIOPHYTIS SA - Sorbonne Université, 4 Place de Jussieu, Paris Cedex 05, 75252, Italy. waly.dioh@biophytis.com.
Stanislas VeilletBIOPHYTIS SA - Sorbonne Université, 4 Place de Jussieu, Paris Cedex 05, 75252, Italy.

Funding

TUFTS--FIELDINGP30AG031679 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI SHALENDER BHASIN · 2008 to 2026
$23.9M
NIA NIH HHS P30 AG031679NIH Boston Claude D. Pepper Center 1P30AG031679US Departement of Agriculture (USDA) 58-8050-9-004
6 · The paper itself

Abstract

backgroundAging is associated with a progressive change of body composition characterized by muscle mass decline and accumulation of adipose tissue that can lead to sarcopenia and obesity, respectively. The prevalence of sarcopenia is poorly known given the different parameters and thresholds in proposed definitions. The combination of obesity (defined as a percentage of body fat mass of > 25% in men and > 35% in women) and sarcopenia (SO) adds complexity to the characterization of this pathology. SARA-OBS aimed to better characterize sarcopenia (including SO) and its consequences on physical function over time, in community-dwelling older adults at risk of mobility disability, and to support the design of further interventional clinical trials.

methodsThis was an international, multicenter, 6-month observational study of men and women aged ≥ 65 years suffering from sarcopenia according to the Foundation for the National Institute of Health (FNIH) cut-offs for Sarcopenia and with a Short Physical Performance Battery (SPPB) ≤ 8. The primary endpoint was the change in Gait Speed (GS) in the 400-meter walking test (400MWT), reported at baseline and at Month 6/ end of the study (EOS). Secondary endpoints included changes in handgrip strength (HGS), physical performance (6-Minute Walking Distance [6MWD], SPPB), the Physical Function Domain (PF-10) sub-score and total score of the SF-36 survey and the Sarcopenia and Quality of Life (SarQoL) questionnaire.

resultsOverall, the mean (± SD) change from baseline to Month 6/EOS in 400MWT GS was - 0.027 ± 0.171 m/sec (p = 0.064). Both GS and 6MWD decreased significantly in subgroup with GS ≥ 0.8 m/sec at baseline (-0.047 ± 0.185 m/sec; p = 0.017 and - 24.01 ± 68.24 m; p = 0.001, respectively). In subgroup with SPPB = 8 at baseline, 6MWD also decreased (-36.80 ± 67.60 m; p < 0.001). We observed a significant change from baseline for 6MWD in the SO subgroup (-18.30 ± 81.95 m; p = 0.013). Neither HGS nor SarQoL changed significantly from baseline to Month 6/EOS.

conclusionsSARA-OBS results contribute to defining subgroups of older adults at risk of functional decline over 6 months, specifically subjects with SPPB = 8, affecting GS and the 6MWD. Additionally, the SO subpopulation exhibited a relevant deterioration in physical function as evaluated by the 6MWD.

trial registrationNCT03021798 (ClinicalTrials.gov). Date of registration 16/01/2017.

Indexed as

Mobility LimitationObesitySarcopeniaAgedAged, 80 and overFemaleHand StrengthHumansMaleRisk FactorsWalking SpeedMobility disabilityOlder adultsPhysical performanceSarcopeniaSarcopenic obesity

Identifiers

PMID40759914
PMCPMC12323141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.